MarketCap
Facebook
X
Telegram
Country |
 USA |
IPO year |
- |
Industry |
Biotechnology |
Stock Exchange |
NASDAQ GLOBAL |
Shares |
39.3 M |
Market Cap[1] |
$ 1.61 M |
EBITDA (LTM) |
- |
P/E (LTM) |
- |
P/S (LTM) |
- |
EPS (LTM) |
- |
Other stocks of industry "Biotechnology"
| Issuer | Price | % 24h | Market Cap | Exchange | Country | |
|---|---|---|---|---|---|---|
 |
CEL-SCI Corporation
CVM
|
$ 1.62 | 4.52 % | $ 13 M | NYSE American,SPB | USA |
 |
Dr. Reddy's Laboratories Limited
RDY
|
$ 13.19 | -0.57 % | $ 11 B | NYSE |  India |
 |
Replimune Group
REPL
|
$ 11.72 | 2.63 % | $ 1.09 B | Nasdaq Global Select Market | USA |
 |
Rigel Pharmaceuticals
RIGL
|
$ 48.88 | 1.6 % | $ 879 M | Nasdaq Global Select Market | USA |
 |
Gilead Sciences
GILD
|
$ 153.57 | -1.88 % | $ 191 B | Nasdaq Global Select Market,SPB | USA |
 |
Entera Bio Ltd.
ENTX
|
$ 3.05 | 0.99 % | $ 141 M | Nasdaq Capital Market |  Israel |
 |
Evogene Ltd.
EVGN
|
$ 0.37 | -0.32 % | $ 2.91 M | Nasdaq Global Market | Israel |
 |
Fate Therapeutics
FATE
|
$ 2.07 | 0.49 % | $ 246 M | Nasdaq Global Market,SPB | USA |
 |
Daré Bioscience
DARE
|
$ 0.69 | -0.15 % | $ 7.71 M | Nasdaq Capital Market | USA |
 |
Sol-Gel Technologies Ltd.
SLGL
|
$ 65.72 | -0.14 % | $ 183 M | Nasdaq Global Select Market | Israel |
 |
Silence Therapeutics plc
SLN
|
$ 19.67 | 0.31 % | $ 2.79 B | Nasdaq Global Select Market |  Britain |
 |
Sanofi
SNY
|
$ 40.97 | -1.04 % | $ 50 B | Nasdaq Global Select Market |  France |
 |
Anavex Life Sciences Corp.
AVXL
|
$ 1.36 | -2.21 % | $ 116 M | Nasdaq Capital Market | USA |
 |
Syros Pharmaceuticals
SYRS
|
- | -8.44 % | $ 3.4 M | Nasdaq Global Select Market | USA |
 |
Spruce Biosciences
SPRB
|
$ 42.73 | 3.64 % | $ 32.8 M | Nasdaq Global Select Market | USA |
 |
Spero Therapeutics
SPRO
|
$ 1.17 | -4.1 % | $ 65.5 M | Nasdaq Global Select Market | USA |
 |
Sutro Biopharma
STRO
|
$ 10.79 | -6.5 % | $ 91.7 M | Nasdaq Global Select Market | USA |
 |
Shattuck Labs
STTK
|
$ 5.58 | -4.45 % | $ 388 M | Nasdaq Global Select Market | USA |
 |
China SXT Pharmaceuticals
SXTC
|
$ 0.07 | 11.79 % | $ 47.6 K | Nasdaq Global Select Market |  China |
 |
Gossamer Bio
GOSS
|
$ 9.79 | 2.19 % | $ 2.24 B | Nasdaq Global Select Market,SPB | USA |
 |
Hutchison China MediTech Limited
HCM
|
$ 14.37 | -2.51 % | $ 12.3 B | Nasdaq Global Select Market | China |
 |
Bio-Techne Corporation
TECH
|
$ 72.64 | 0.08 % | $ 11.3 B | Nasdaq Global Select Market,SPB | USA |
 |
Tenax Therapeutics
TENX
|
$ 1.63 | 2.15 % | $ 63.9 M | Nasdaq Global Select Market | USA |
 |
Gamida Cell Ltd.
GMDA
|
- | -18.25 % | $ 5.04 M | Nasdaq Global Market | Israel |
 |
Teva Pharmaceutical Industries Limited
TEVA
|
$ 40.62 | -0.56 % | $ 46.5 B | NYSE | Israel |
 |
TG Therapeutics
TGTX
|
$ 53.2 | -2.44 % | $ 7.68 B | Nasdaq Capital Market | USA |
 |
Heron Therapeutics
HRTX
|
$ 0.34 | -4.43 % | $ 56.7 M | Nasdaq Global Select Market,SPB | USA |
 |
Tonix Pharmaceuticals Holding Corp.
TNXP
|
$ 5.43 | -6.06 % | $ 46.2 M | Nasdaq Global Select Market | USA |
 |
Trevi Therapeutics
TRVI
|
$ 12.77 | -0.47 % | $ 1.72 B | Nasdaq Global Market | USA |
 |
Taysha Gene Therapies
TSHA
|
$ 4.12 | 0.24 % | $ 1.32 B | Nasdaq Global Select Market | USA |
|
Enlivex Therapeutics Ltd.
ENLV
|
$ 0.2 | -9.61 % | $ 9.14 M | Nasdaq Capital Market | Israel |
 |
Aridis Pharmaceuticals
ARDS
|
- | 17.91 % | $ 11.1 M | Nasdaq Capital Market | USA |
 |
Innoviva
INVA
|
$ 20.91 | -1.74 % | $ 1.41 B | Nasdaq Global Select Market | USA |
 |
Genmab A/S
GMAB
|
$ 39.57 | 1.28 % | $ 2.56 B | Nasdaq Global Select Market |  Danmark |
 |
UroGen Pharma Ltd.
URGN
|
$ 35.48 | 1.34 % | $ 1.71 B | Nasdaq Global Select Market | Israel |
 |
United Therapeutics Corporation
UTHR
|
$ 563.49 | 1.74 % | $ 25 B | Nasdaq Global Select Market,SPB | USA |
 |
Citius Pharmaceuticals
CTXR
|
$ 0.4 | -5.27 % | $ 4.43 M | Nasdaq Capital Market | USA |
 |
Akouos
AKUS
|
- | 0.23 % | $ 488 M | Nasdaq Global Select Market | USA |
 |
Bellerophon Therapeutics
BLPH
|
- | -74.18 % | $ 955 K | Nasdaq Capital Market | USA |
 |
Vericel Corporation
VCEL
|
$ 40.94 | 0.89 % | $ 2.06 B | Nasdaq Global Select Market,SPB | USA |
 |
Veracyte
VCYT
|
$ 46.22 | 3.19 % | $ 3.63 B | Nasdaq Global Market,SPB | USA |
 |
Ironwood Pharmaceuticals
IRWD
|
$ 3.55 | -2.2 % | $ 575 M | Nasdaq Global Select Market | USA |
 |
Vir Biotechnology
VIR
|
$ 10.57 | -1.58 % | $ 1.46 B | Nasdaq Global Select Market,SPB | USA |
 |
Viking Therapeutics
VKTX
|
$ 26.38 | -1.24 % | $ 2.97 B | Nasdaq Capital Market | USA |
 |
Vanda Pharmaceuticals
VNDA
|
$ 4.01 | -3.84 % | $ 236 M | Nasdaq Global Select Market,SPB | USA |
 |
Johnson & Johnson
JNJ
|
$ 257.78 | -0.6 % | $ 621 B | NYSE,SPB | USA |
 |
Verrica Pharmaceuticals
VRCA
|
$ 3.63 | 4.61 % | $ 38.7 M | Nasdaq Global Market | USA |
 |
Viridian Therapeutics
VRDN
|
$ 23.01 | 2.59 % | $ 2.34 B | Nasdaq Capital Market | USA |
 |
Verastem
VSTM
|
$ 9.21 | -1.39 % | $ 638 M | Nasdaq Global Market | USA |
 |
VistaGen Therapeutics
VTGN
|
$ 0.19 | -2.12 % | $ 7.23 M | Nasdaq Global Select Market | USA |
References
- Pavone, P. (2019). Market capitalization and financial variables: Evidence from Italian listed companies. International Journal of Academic Research Business and Social Sciences, 9(3), 1356-1371.